tirzepatide scholarly articles as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real‐World Evidence Tirzepatide - The International Peptide

These cardiovascular benefits make these medications an attractive option for individuals with obesity and type 2 diabetes who are at risk for heart disease

For those planning to make the change, our semaglutide to tirzepatide conversion chart walks through the transition step by step

It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Most people notice visible changes between weeks 6 and 12, though the timeline depends on starting weight, dose, and individual physiology

J Cardiovasc Pharmacol 2022;80:171-9